Skip to main content
SearchLogin or Signup

A Nootropic Formula for the Treatment of Attention Deficit Disorder

A Nootropic Formulation with Pro-Cholinergic Dopamine and Serotonin Receptoral Sensitivity Enhancement Features along with the elevation of Beta-Endorphin Release

A Nootropic Formula for the Treatment of Attention Deficit Disorder

Description

A COMPOSITION FOR THE TREATMENT OF ATTENTION AND CONCENTRATION DEFICIT DISORDERS

Technical Field

The invention relates to a composition formed for the treatment of attention and concentration deficit disorders.

The invention relates in particular to a composition formed for the use of alpha-methyl-tyrosine ethyl ester, dimethylsalidroside and puerarin derivative for the treatment of attention and concentration deficit disorders.

State of the Art

In today’s increasingly rapid pace of life, profound decreases are encountered in the number of people who are happy with their lives, while the complaints about the life are increasing to the same extent. The individuals from every age, from the children to the adults, complain about the deficits in their mental activities. Some complain about forgetfulness and the lack of attention, while some others complain about being unable to be motivated. However, “the concentration deficit” is observed to be the most notable one among the issues of complaint.

Today, the drugs such as antidepressants, venlafaxine and bupropion are preferred for the drug treatment of the attention deficit and their doses and the ways of use are determined according to the phase of the disease in the individual.

The invention no. EP2016418B1 entitled "In vitro procedure for diagnosis and early diagnosis of neurodegenerative diseases" provides an in vitro process for the detection and early detection of neurodegenerative diseases, for determination of the severity, and to evaluate the progression of and render a prognoses of neurodegenerative diseases, in a patient suffering from a subjectively or objectively detectable cognitive impairment, by determining the concentration of an analyte selected from natriuretic peptides, in particular ANP, and, if necessary, BNP and/or CNP in a biological fluid of the patient, whereby the determination of the analyte is performed directly and/or indirectly as the determination of a relevant co-peptide generated from a mutual propeptide, and is based upon the measured concentration of the determined analyte thus making it possible to form conclusions about a neurodegenerative disease or an early form typical of such a disease or the course of the disease and/or the success of the efforts to relieve or prevent the disease.

The invention no. EP1392314B1 entitled "Novel use of 2-[2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on" relates to the use of PDE 5 inhibitors in general and in particular 2-phenyl-substituted imidazotriazinones for producing a medicament for improving cognition, concentration capacity, learning capacity and/or memory retentiveness, in particular for the treatment and/or prophylaxis of cognition, concentration capacity, learning capacity and/or memory retentiveness disorders.

As a result, the presence of the need for a composition formed for the use of alpha-methyl-tyrosine ethyl ester, dimethylsalidroside and puerarin derivative for the treatment of attention and concentration deficit disorders and the inadequacy of the existing solutions have made it necessary to perform an improvement in the relevant art.

Object of the Invention

In order to eliminate the disadvantages of the state of the art, an object of the invention is to treat the attention and concentration deficit disorders.

Another object of the invention is to promote the production of dopamine.

Another object of the invention is to promote the production of norepinephrine.

Another object of the invention is to trigger the production of dopamine and preserve the dopaminergic receptor sensitivity.

Another object of the invention is to increase the serotonin receptor sensitivity.

Another object of the invention is to increase the release of acetylcholine owing to the ability to trigger the release of beta-endorphin.

In order to achieve the aforesaid advantages, the invention is a composition for the treatment of attention and concentration deficit disorders, said composition being obtained by the components selected from the group comprising alpha-methyl-tyrosine ethyl ester, dimethylsalidroside and puerarin derivative that are used individually or in combinations.

The structural and characteristic features and all the advantages of the invention will become more clearly understood from the detailed description provided below and therefore, the evaluation must be made taking this detailed description into consideration.

Detailed Description of the Invention

The invention is a composition formed for the treatment of attention and concentration deficit disorders. The composition according to the invention contains alpha-methyl-tyrosine ethyl ester, dimethylsalidroside, 11-methoxypuerarin.

Alpha-methyl-tyrosine ethyl ester, an ingredient of the composition according to the invention, promotes the production of dopamine. Alpha-methyl-tyrosine ethyl ester also promotes the production of norepinephrine. Dimethylsalidroside, another ingredient of the invention, triggers the production of dopamine and preserves the dopaminergic receptor sensitivity.

11-methoxypuerarin, a puerarin derivative, another ingredient of the invention, increases the serotonin receptor sensitivity. 11-methoxypuerarin also increases the release of acetylcholine owing to the ability to trigger the release of beta-endorphin.

Said formulation is obtained by a mixture of the aforesaid components according to the following ratios by weight:

15-43% alpha-methyl-tyrosine ethyl ester,

16-27% dimethylsalidroside,

69-30% 11-methoxypuerarin.

The composition is obtained from the aforesaid components selected from the aforesaid group and used according to the mentioned weight ratio ranges individually or in combinations.

Said invention also encompasses the use of said composition for treating attention and concentration deficit disorders and the manufacture thereof for this purpose.


CLAIMS

  1. A composition for the treatment of attention and concentration deficit disorders, said composition being obtained by the components selected from the group comprising alpha-methyl-tyrosine ethyl ester, dimethylsalidroside and puerarin derivative that are used individually or in combinations.

  2. A composition according to Claim 1 characterized in that it comprises 15-43% by weight alpha-methyl-tyrosine ethyl ester.

  3. A composition according to Claim 1 characterized in that it comprises 16-27% by weight dimethylsalidroside.

  4. A composition according to Claim 1 characterized in that it comprises 11-methoxypuerarin.

  5. A composition according to Claims 1 and 4 characterized in that it comprises 69-30% by weight 11-methoxypuerarin.

  6. Use of the components according to Claims 1 to 5 obtained individually or in combinations from the group consisting of alpha-methyl-tyrosine ethyl ester, dimethylsalidroside, 11-methoxypuerarin for the manufacture of a composition for treating attention and concentration deficit disorders.

ABSTRACT

A COMPOSITION FOR THE TREATMENT OF ATTENTION AND CONCENTRATION DEFICIT DISORDERS

The invention relates to a composition formed for the treatment of attention and concentration deficit disorders.

No figure.

Comments
0
comment

No comments here